THERE ARE MANY misconceptions about important cardiovascular metrics. Often people think their risk of heart disease and ...

Indeed, both non-HDL-C and apo B have been proposed as secondary treatment targets after LDL-C goals have been achieved. The EPIC-Norfolk investigation was used to select cases, who were ...

The defining protein of LDL is a single copy of apolipoprotein B-100 (apoB-100), one of the largest translated proteins in the human genome. ApoB-100’s massive size and association with lipids ...

They also had 16% higher levels of LDL cholesterol in their blood than the control group and 26% higher levels of ...

2 Department of Movement Sciences, Maastricht University, Maastricht, the Netherlands 3 Department of Endocrinology, University Hospital Groningen, Groningen, the Netherlands Correspondence to: Dr ...

There was a 21% reduction in MACE, an exploratory endpoint, in the obicetrapib group vs placebo after 1 year. Obicetrapib ...

Study deciphers the molecular handshake between LDL receptors and apoB100, shedding light on cholesterol metabolism and its role in cardiovascular disease. Study: Structure of apolipoprotein B100 ...

Lp(a), a genetically driven variant of low-density lipoprotein (LDL ... It also lowered apolipoprotein(b), or “bad” cholesterol, levels. Developed by Eli Lilly, muvalaplin offers a non ...

Finally, all statistical models included apo B to account for differences in the proatherogenic lipoprotein fraction. In the IDEAL study, we observed that plasma levels of HDL-C were indeed ...

lipoprotein(a), apolipoprotein B, and apolipoprotein A1, were also found to be consistent with previous clinical trials. Notably, there was a 21% reduction in major adverse cardiovascular events ...